CLEVELAND, Jan. 23 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that Chief Scientist Andrei Gudkov, Ph.D., D. Sci., was interviewed by The video podcast can be accessed at the Cleveland BioLabs website at www.cbiolabs.comor at

Dr. Gudkov highlighted the Company's recent discovery regarding its Protectans 600 series of compounds being developed for radiation protection. A single administration of CBLB612, the lead compound in the Protectans 600 series, in healthy mice resulted in a three-fold increase in the number of progenitor (originator) stem cells in mouse bone marrow within 24 hours after administration. Moreover, the number of these stem cells in peripheral blood was increased 10-fold within four days of administration. This research indicates that CBLB612 and other compounds in the 600 series are not only potent stimulators of bone marrow stem cells, but also cause their mobilization and proliferation throughout the blood.

Cleveland BioLabs's Protectans 600 series are modified factors of Mycoplasmas. Protectan CBLB612 has demonstrated both radiation protection and mitigation properties over a very broad time window of use. In animal experiments, Protectan CBLB612 has produced complete and sustained recovery of the hematopoietic (bone marrow/blood production) system following lethal doses of radiation.

Dr. Gudkov also discussed the Company's strategic research partnership with Roswell Park Cancer Institute to develop the Company's cancer and radio- protectant drug candidates. Roswell Park and various agencies of the state of New York will provide Cleveland BioLabs with up to $5 million of non-dilutive funding. Cleveland BioLabs will establish a major research/clinical facility at the Roswell Park campus in Buffalo, NY, which will become the foundation for its advanced research and clinical trials. The Company will have an open- ended license to any basic research conducted within or in collaboration with its Roswell Park laboratory.

Roswell Park Cancer Institute (RPCI), founded in 1898, is a world-renowned cancer research hospital and the nation's first cancer research, treatment and education center. RPCI is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers and is one of only 10 free-standing cancer centers in the nation.

Other pending developments noted in the interview include a Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of Acute Radiation Syndrome (ARS) from The Department of Defense (DoD). The DoD published a pre-solicitation notice on December 20, 2006, indicating that this RFP will be issued on or about January 10, 2007, with an anticipated contract award on or about July 20, 2007.

Cleveland BioLabs' lead radiation protection compound, Protectan CBLB502, is currently being developed to treat ARS and will be submitted to the DoD. CBLB502 is effective as a radioprotectant when administered as little as 15 minutes prior to exposure and as a mitigator, if administered up to one hour after exposure. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation-induced damage.

In addition, CBLB502 is stable in sterilized solution, not requiring refrigeration, and could be injected using self-injectable devices, which are the preferred delivery system in the field. Moreover, the compound does not display toxicity at therapeutic doses.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding potential benefits of the research partnership. Forward-looking statements often are preceded by words such as "believes," "expects," "may," "anticipates," "plans," "intends," "assumes," "will" or similar expressions. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward- looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006.

     The Global Consulting Group
     Rachel Levine
     T: (646) 284-9439